Neal Edward Ready, MD, PhD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 25178 Morris Bldg-200 Trent Dr., Box 3198, Durham, NC 27710
Phone (919) 681-6932
Email address neal.ready@duke.edu
In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Tufts University, 1992 - 1994
  • Fellow in Hematology-Oncology, Medicine, Brown University, 1990 - 1992
  • Medical Resident, Medicine, Brown University, 1986 - 1989
  • M.D., Vanderbilt University, 1986
  • Ph.D., University of California at Irvine, 1983
Weight
-20

Publications

Ready, Neal E., Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott J. Antonia, et al. “Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort..” J Thorac Oncol, October 17, 2019. https://doi.org/10.1016/j.jtho.2019.10.004.

PMID
31629915
Full Text

Jacobs, C. D., J. Gao, X. Wang, N. E. Ready, J. Clarke, B. Tong, C. R. Kelsey, G. Suneja, and J. A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-Small Cell Lung Cancer: Patterns of Care and Comparative Effectiveness Analyses Using the National Cancer Database.” In International Journal of Radiation Oncology*Biology*Physics, 104:243–243. Elsevier BV, 2019. https://doi.org/10.1016/j.ijrobp.2019.01.042.

Full Text

Ready, Neal, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, et al. “First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers..” J Clin Oncol 37, no. 12 (April 20, 2019): 992–1000. https://doi.org/10.1200/JCO.18.01042.

PMID
30785829
Full Text

Siu, Lillian L., Caroline Even, Ricard Mesía, Eva Remenar, Amaury Daste, Jean-Pierre Delord, Jürgen Krauss, et al. “Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial..” Jama Oncol 5, no. 2 (February 1, 2019): 195–203. https://doi.org/10.1001/jamaoncol.2018.4628.

PMID
30383184
Full Text

Khoury, Tawfiq, David Jang, Ricardo Carrau, Neal Ready, Ian Barak, and Ralph Abi Hachem. “Role of induction chemotherapy in sinonasal malignancies: a systematic review..” Int Forum Allergy Rhinol 9, no. 2 (February 2019): 212–19. https://doi.org/10.1002/alr.22229.

PMID
30411867
Full Text

Ready, Neal, Anna F. Farago, Filippo de Braud, Akin Atmaca, Matthew D. Hellmann, Jeffrey G. Schneider, David R. Spigel, et al. “Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032..” J Thorac Oncol 14, no. 2 (February 2019): 237–44. https://doi.org/10.1016/j.jtho.2018.10.003.

PMID
30316010
Full Text

Zandberg, Dan P., Alain P. Algazi, Antonio Jimeno, James S. Good, Jérôme Fayette, Nathaniel Bouganim, Neal E. Ready, et al. “Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy..” European Journal of Cancer (Oxford, England : 1990) 107 (January 2019): 142–52. https://doi.org/10.1016/j.ejca.2018.11.015.

PMID
30576970
Full Text

Liu, Stephen V., D Ross Camidge, Scott N. Gettinger, Giuseppe Giaccone, Rebecca S. Heist, F Stephen Hodi, Neal E. Ready, et al. “Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer..” Eur J Cancer 101 (September 2018): 114–22. https://doi.org/10.1016/j.ejca.2018.06.033.

PMID
30053670
Full Text

Tan, Irena, Tom Stinchcombe, Neal E. Ready, Michael B. Datto, Rebecca J. Nagy, Lin Gu, and Jeffrey Melson Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study..” In Journal of Clinical Oncology, 36:e21222–e21222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21222.

Full Text

Siu, L., C. Even, R. Mesia, A. Daste, J. Krauss, N. F. Saba, L. Nabell, et al. “A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR.” In International Journal of Radiation Oncology Biology Physics, 100:1307–1307. ELSEVIER SCIENCE INC, 2018.

Scholars@Duke

Pages